The development of successful formulations for delivery of siRNA inhibiting synthesis of transthyretin (TTR) in hepatocytes took at least two decades but became the first approved liposomal siRNA therapy for transthyretin-mediated amyloidosis, Patisiran (marketed as Onpattro) [139]. The gene discussed is TTR; the disease is amyloidosis.